These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 27803638)

  • 41. Cost effectiveness of glatiramer acetate and natalizumab in relapsing-remitting multiple sclerosis.
    Earnshaw SR; Graham J; Oleen-Burkey M; Castelli-Haley J; Johnson K
    Appl Health Econ Health Policy; 2009; 7(2):91-108. PubMed ID: 19731967
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A longitudinal real-life comparison study of natalizumab and fingolimod.
    Lanzillo R; Carotenuto A; Moccia M; Saccà F; Russo CV; Massarelli M; De Rosa A; Brescia Morra V
    Acta Neurol Scand; 2017 Sep; 136(3):217-222. PubMed ID: 27976804
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Switching from natalizumab to fingolimod: an observational study.
    Sempere AP; Martín-Medina P; Berenguer-Ruiz L; Pérez-Carmona N; Sanchez-Perez R; Polache-Vengud J; Feliu-Rey E
    Acta Neurol Scand; 2013 Aug; 128(2):e6-e10. PubMed ID: 23336398
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Drug-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients.
    Oshima Y; Tanimoto T; Yuji K; Tojo A
    Mult Scler; 2019 Jul; 25(8):1141-1149. PubMed ID: 29985084
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells.
    Spadaro M; Caldano M; Marnetto F; Lugaresi A; Bertolotto A
    J Neuroinflammation; 2015 Aug; 12():146. PubMed ID: 26259673
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [[Natalizumab therapy, 2013].
    Karácsony M; Bencsik K; Vécsei L
    Ideggyogy Sz; 2014 Jul; 67(7-8):220-8. PubMed ID: 25509362
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Risk of early relapse following the switch from injectables to oral agents for multiple sclerosis.
    Spelman T; Mekhael L; Burke T; Butzkueven H; Hodgkinson S; Havrdova E; Horakova D; Duquette P; Izquierdo G; Grand'Maison F; Grammond P; Barnett M; Lechner-Scott J; Alroughani R; Trojano M; Lugaresi A; Granella F; Pucci E; Vucic S;
    Eur J Neurol; 2016 Apr; 23(4):729-36. PubMed ID: 26782663
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy.
    Dong-Si T; Gheuens S; Gangadharan A; Wenten M; Philip J; McIninch J; Datta S; Richert N; Bozic C; Bloomgren G; Richman S; Weber T; Clifford DB
    J Neurovirol; 2015 Dec; 21(6):637-44. PubMed ID: 25771865
    [TBL] [Abstract][Full Text] [Related]  

  • 50. PML-IRIS during Fingolimod Diagnosed after Natalizumab Discontinuation.
    Killestein J; Vennegoor A; van Golde AE; Bourez RL; Wijlens ML; Wattjes MP
    Case Rep Neurol Med; 2014; 2014():307872. PubMed ID: 25506447
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Update on disease-modifying therapies for multiple sclerosis.
    Vargas DL; Tyor WR
    J Investig Med; 2017 Jun; 65(5):883-891. PubMed ID: 28130412
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alternatives for reducing relapse rate when switching from natalizumab to fingolimod in multiple sclerosis.
    Fragoso YD; Adoni T; Alves-Leon SV; Apostolos-Pereira SL; Araujo YR; Becker J; Brooks JBB; Correa EC; Damasceno A; Damasceno CAA; Ferreira MLB; Gama PDD; Gama RADD; Gomes S; Goncalves MVM; Grzesiuk AK; Machado SCN; Matta APDC; Mendes MF; Ribeiro TAGJ; Rocha CFD; Ruocco HH; Sato H; Simm RF; Tauil CB; Vasconcelos CCF; Vieira VLF
    Expert Rev Clin Pharmacol; 2016 Apr; 9(4):541-546. PubMed ID: 26794493
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab.
    Ottenlinger FM; Mayer CA; Ferreirós N; Schreiber Y; Schwiebs A; Schmidt KG; Ackermann H; Pfeilschifter JM; Radeke HH
    Front Pharmacol; 2016; 7():412. PubMed ID: 27857690
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The clinical meaning of walking speed as measured by the timed 25-foot walk in patients with multiple sclerosis.
    Cohen JA; Krishnan AV; Goodman AD; Potts J; Wang P; Havrdova E; Polman C; Rudick RA
    JAMA Neurol; 2014 Nov; 71(11):1386-93. PubMed ID: 25178496
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment patterns in multiple sclerosis: administrative claims analysis over 10 years.
    Oleen-Burkey M; Cyhaniuk A; Swallow E
    J Med Econ; 2013; 16(3):397-406. PubMed ID: 23301877
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Shortening the washout to 4 weeks when switching from natalizumab to fingolimod and risk of disease reactivation in multiple sclerosis.
    Naegelin Y; Rasenack M; Andelova M; Von Felten S; Fischer-Barnicol B; Amann M; Mehling M; Kappos L; Sprenger T; Derfuss T
    Mult Scler Relat Disord; 2018 Oct; 25():14-20. PubMed ID: 30014876
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.
    Zivadinov R; Hojnacki D; Bergsland N; Kennedy C; Hagemeier J; Melia R; Ramasamy DP; Durfee J; Carl E; Dwyer MG; Weinstock-Guttman B
    Eur J Neurol; 2016 Jun; 23(6):1101-9. PubMed ID: 26998905
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
    Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D
    Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real-life clinical use of natalizumab and fingolimod in Austria.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T
    Acta Neurol Scand; 2018 Feb; 137(2):181-187. PubMed ID: 29159801
    [TBL] [Abstract][Full Text] [Related]  

  • 60. JC polyomavirus expression and bell-shaped regulation of its SF2/ASF suppressor during the follow-up of multiple sclerosis patients treated with natalizumab.
    Uleri E; Ibba G; Piu C; Caocci M; Leoni S; Arru G; Serra C; Sechi G; Dolei A
    J Neurovirol; 2017 Apr; 23(2):226-238. PubMed ID: 27812788
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.